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Systemic mastocytosis (SM) is a clinically heterogeneous group of disorders characterized by 
the accumulation of clonal MC in bone marrow (BM), and frequently also in other organs 
including the skin and/or the gastrointestinal tract. Currently, the clonal nature of the disease 
can be clearly established in most SM patients through the demonstration of somatic 
activating mutations involving the tyrosin-kinase regulatory domain of the Kit receptor. In 
most cases, such KIT mutations lead to continuously ligand-independent 
autophosphorylation of the receptor, and initiation of downstream signalling events resulting 
in the release of MC-mediators. In recent years, detailed clinical, biological and molecular 
characterization of MC activation syndromes (MCAS) not fulfilling enough criteria for SM has 
been made. Based on the presence or absence of KIT mutations, MCAS are currently 
classified into clonal MCAS (c-MCAS) and non-clonal MCAS (nc-MCAS). Unlike BM MC from SM 
patients, in which aberrant CD25 expression and cytomorphological abnormalities, together 
with KIT mutations, are usually detected, BM MC from both c-MCAS and nc-MCAS cases 
frequently show a normal morphological appearance and/or immunophenotype. Patients with 
SM and MCAS suffer from systemic, usually recurrent symptoms, which are attributable to the 
release of MC mediators; Noteworthy, vasoconstriction-related features, such as increase of 
blood pressure, can be occasionally observed in a few patients during acute MC activation 
episodes. Moreover, neurological ischemic symptoms suggesting a transient cerebral 
vasospasm have been recently reported in two patients diagnosed with indolent SM (ISM) and 
nc-MCAS, respectively. Altogether, these observations provide strong evidence that Kounis 
syndrome (KS) which denotes acute coronary events as a result mast cell mediator 
action might also occur in patients with MC-related disorders. Herein, we report a series of 10 
patients with different MC-related disorders, who presented with acute coronary syndromes 
as an unusual manifestation of their MC-mediator symptomatology profile. To the best of our 
knowledge, this is the first series of KS presenting in patients with SM and MCAS reported so 
far. A total of 10 patients (six males and four females) with a median age of 57 years (range: 36 
to 74 years) with a history of oppressive chest pain suggesting an ischemic heart event, who 
were referred to the Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) 
between July 2007 and March 2012 because of a suspected underlying MC disorder (e.g. SM or 
MCAS) based on clinical symptoms and/or serum tryptase levels, were included in the study. 
At referral to the CLMast, patients were carefully explored for the presence of skin lesions 
suggestive of mastocytosis, and MC-mediator release symptoms were recorded. In addition, 
baseline serum tryptase (Phadia Diagnostics, Uppsala, Sweden) and total serum IgE levels were 
measured in all cases, while specific IgE (immunoCAP, Phadia Diagnostics) was investigated, at 
the time it was commercially available, in those cases in which triggers potentially causing an 
IgE-mediated reaction (e.g. food, insect stings or drugs), were identified. Specific serum IgE 
values > 0.35 KU/L were considered as positive. In order to properly classify the underlying MC 
disorder, a complete BM study was performed in 9/10 patients, following recently proposed 
criteria, which included assessment of BM MC morphology in toluidine blue and May–
Grünwald–Giemsa stained smears, evaluation of the presence of focal dense BM MC 
aggregates (> 15 MC per cluster) in BM sections stained for c-kit and tryptase, 
immunophenotypical analysis of CD25 and CD2 expression on BM MC by flow cytometry 
according to consensus criteria previously defined by the Spanish Network on Mastocytosis 
(REMA) and the investigation of somatic activating codon Asp816 → Val KIT mutation in 
genomic DNA from fluorescence-activated cell sorting-purified BM MC, performed as describe 
elsewhere. 
Diagnosis of SM was made strictly following the current World Health Organization (WHO) 
accepted criteria; by contrast, MCAS was diagnosed in cases not fulfilling enough criteria for 
SM, and MCAS patients were further subclassified as c-MCAS or nc-MCAS based on the 
presence vs. absence of mutated BM MCs, according to recent recommendations. 
The clinical and laboratory findings of the 10 patients presenting with mast cell-related 
disorders and Kounis syndrome are shown in table 1.  
 
In our series, ACS triggered by drugs, hymenoptera venom and foods was documented in most 
cases, which is in agreement with the most frequently observed causes of KS, reported in the 
literature. According to coronary arteriography findings, 3 of such patients were classified as 
type I variant KS, one as type II variant and 4 cases remain unclassifiable because 
coronariography was not performed. In turn, the remaining two patients suffered from effort-
induced ACS with no additional identifiable allergenic triggers in the setting of both an 
underlying atheromatous disease and a clonal MC disorder (ISM and c-MCAS, respectively). 
Although these two cases mimicked typical stable angina, a potential role of MC-mediator 
release in the genesis of ACS could not be ruled out, since exercise is an infrequent but well-
recognized trigger of MC-mediator release in patients with anaphylaxis. 
Increased tryptase levels (> 11.4 μg/L) were detected in most cases included in our series. 
Unlike ISM cases, in which elevated baseline tryptase levels could be explained by chronic 
release by an increased number of MC, patients with MCAS usually have a low or even very 
low, MC burden. In this regard, it has been suggested that tryptase released by MC might 
contribute to control and prevent exaggerated allergic reactions through cleavage of IgE; 
whether this mechanism could also occur in patients with MCAS in between acute MC-
mediator release episodes, remains unknown. 
Kounis syndrome is increasingly reported in clinical practice, but little is known about its 
association with MC disorders. Routine determination of serum tryptase levels during acute 
coronary symptoms might provide evidence for a potential role of MC activation in the 
pathogenesis of ACS in a subset of patients. Further investigations are warranted in order to 
assess the utility of antimediator drugs in the management of these subjects. 
 
